中东呼吸综合征治疗药物研究进展

Research Advancement in the Therapeutic Drugs Against Middle East Respiratory Syndrome

中东呼吸综合征(MERS)是由中东呼吸综合征冠状病毒(MERS-CoV)引起的急性呼吸道传染病。MERS-CoV是继SARS冠状病毒(SARS-CoV)之后发现的一种具有高致死率的新型病毒,可由单峰骆驼传染给人类。目前,临床尚无抗MERS-CoV的特效药物。抗MERS-CoV的药物开发策略主要是借鉴抗SARS-CoV药物的开发经验,包括疫苗,抗体,小分子化合物快速筛选等。本文结合临床治疗及动物模型对MERS治疗药物的研究进展进行综述,旨在为该病新型疫苗和抗病毒药物的研发提供借鉴。

Middle East Respriatory Syndrome （MERS） was an emerging respiratory infection caused by the new- ly identified MERS CoV. MERS-CoV had a high mortality rate, which could be transmitted from dromedaries to humans. Presently, there was no specific medication for MERS-CoV. The research and development strategies of anti-MERS-CoV drugs mainly were similar to dealing with SARS-CoV, such as vaccines, antibodies and chemical drugs. This article summarized the latest research progress in the animal models and clinical treatment, to provide evidence for designing novel antiviral drugs and vaccines.